Abstract
The influence of route of administration on the absolute bioavailability and GI tract absorption of nitrofurantoin was investigated in rabbits. The disposition of nitrofurantoin was described by a one-compartment model with simultaneous first-order and Michaelis-Menten type elimination kinetics, and bioavailability was estimated by nonlinear assessment. The plasma levels following oral administration were significantly lower than those after intravenous administration, and absolute Fvalues for oral administration were approximately 0.3. However, Fvalues following intraduodenal administration and portal vein infusion were nearly unity, and it was concluded that the reduction of bioavailability following oral administration could not be attributed to metabolism by intestinal microflora or to the hepatic first-pass effect. Thus, reduction of Fvalues following oral administration is probably due to gastric degradation of the drug. The effects of factors influencing bioavailability, such as water volume taken with the drug, change of gastric emptying rate and effect of particle size, were also investigated. Increase of volume of water administered tended to improve the bioavailability, and a particle size dependency was also observed.
Similar content being viewed by others
References
G. L. Mattok, R. D. Hossie, and I. J. McGilveray.In vivo:in vitro studies of nitrofurantoin tablets.Can. J. Pharm. Sci. 7:84–87 (1972).
R. G. Stoll, T. R. Bates, and J. Swarbrick.In vitro dissolution andin vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates.J. Pharm. Sci. 62:65–68 (1973).
T. R. Bates, H. A. Rosenberg, and A. V. Tembo. Inconsistencies in rationale underlying official USP dissolution rate specifications for nitrofurantoin.J. Pharm. Sci. 62:2057–2058 (1973).
T. R. Bates, J. M. Young, C. M. Wu, and H. A. Rosenberg. pH-Dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules.J. Pharm. Sci. 63:643–645 (1974).
I. J. McGilveray, G. L. Mattok, and R. D. Hossie. The comparison of the bioavailabilities of commercial nitrofurantoin tablets.Rev. Can. Biol. 32:99–106 (1973).
K. S. Albert, A. J. Sedman, P. Wilkinson, R. G. Stoll, W. J. Murray, and J. G. Wagner. Bioavailability studies of acetaminophen and nitrofurantoin.J Clin. Pharmacol. 14:264–270 (1974).
M. C. Meyer, G. W. A. Slywka, R. E. Dann, and P. L. Whyatt. Bioavailability of 14 nitrofurantoin products.J. Pharm. Sci. 63:1693–1698 (1974).
R. W. Mendes, S. Z. Masih, and R. R. Kanumuri. Effect of formulation and process variables on bioequivalency of nitrofurnatoin II:In vivo-in vitro correlation.J. Pharm. Sci. 67:1616–1619 (1978).
R. Gröning. Control of release and biological availability of drugs—investigations into the renal elimination of nitrofurantoin.Int. J. Pharm. 8:175–181 (1981).
L-K. Chen, D. E. Cadwallader, and H. W. Jun. Nitrofurantoin solubility in aqueous urea and creatinine solutions.J Pharm. Sci. 65:868–872 (1976).
J. A. Buzard, R. C. Bender, E. G. Nohle, D. T. Humphrey, and M. F. Paul. Renal tubular transport of nitrofurantoin.Am. J. Physiol. 202:1136–1140 (1962).
M. F. Paul, R. C. Bender, and E. G. Nohle. Renal excretion of nitrofurantoin (Furadantin).Am. J. Physiol. 197:580–584 (1959).
M. F. Paul, H. E. Paul, R. C. Bender, F. Kopko, C. M. Harrington, V. R. Ells, and J. A. Buzard. Studies on the distribution and excretion of certain nitrofurans.Antibiot. Chemother. 10:287–302 (1960).
D. E. Cadwallader and H. W. Jun. InAnalytical Profiles of Drug Substances, Vol. 3, Flory and Klaus (eds.) Academic Press, New York, 1976, pp. 346–373.
J. D. Conklin and F. J. Hailey. Urinary drug excretion in man during oral dosage of different nitrofurantoin formulations.Clin. Pharmacol. Ther. 10:534–539 (1969).
J. D. Conklin and D. L. Wagner. Excretion of nitrofurantoin in dog hepatic bile.Br. J. Pharmacol. 43:140–150 (1971).
J. D. Conklin, R. J. Sobers, and D. L. Wagner. Further studies on nitrofurantoin excretion in dog hepatic bile.Br. J. Pharmacol. 48:273–277 (1973).
M. B. Aufrere, B-A. Hoener, and M. Vore. Reductive metabolism of nitrofurantoin in the rat.Drug Metab. Disp. 6:403–411 (1978).
N. Watari and N. Kaneniwa. Dissolution of slightly soluble drugs VIII.In vivo drug dissolution in human subjects and rabbits.Int. J. Pharm. 7:307–316 (1981).
A. N. Martin, J. Swarbrick, and A. Cammarata.Physical Pharmacy, 2nd ed. Lea & Febiger, Philadelphia, 1973, pp. 484–485.
T. R. Bates, J. A. Sequeira, and A. V. Tembo. Effect of food on nitrofurantoin absorption.Clin. Pharmacol. Ther. 16:63–68 (1974).
N. Watari, T. Funaki, and N. Kaneniwa. Fluorescence assay of nitrofurantoin with o-aminothiophenol in plasma and urine.J. Pharm. Sci. 69:106–107 (1980).
J. D. Conklin and R. D. Hollifield. A new method for the determination of nitrofurantoin in urine.Clin. Chem. 11:925–931 (1965).
L. Martis and R. H. Levy. Bioavailability calculations for drugs showing simultaneous first-order and capacity-limited elimination kinetics.J. Pharmacokin. Biopharm. 1:283–294 (1973).
S. Øie and D. Jung. Bioavailability under variable renal clearance conditions.J. Pharm. Sci. 68:128–129 (1979).
T. Nakagawa and Y. Oyanagi. Program system “SALS” for nonlinear least-squares fitting in experimental sciences. InAbstracts, International Conference on Statistics, Tokyo, (November 1979), pp. 19–22.
M. L. Henderson, A. L. Picchioni, and L. Chin. Evaluation of oral dilution as a first acid measure in poisoning.J. Pharm. Sci. 55:1311–1313 (1966).
J. M. Jaffe. Effect of propantheline on nitrofurantoin absorption.J. Pharm. Sci. 64: 1729–1730 (1975).
H. E. Paul, K. J. Hayes, M. F. Paul, and A. R. Borgmann. Laboratory studies with nitrofurantoin. Relationship between crystal size, urinary excretion in the rat and man, and emesis in dogs.J. Pharm. Sci. 56:882–885 (1967).
Y. Imamura, L. H. Wang, C. S. Lee, and J. H. Perrin. Effects of chlorpromazine and atropine on acetaminophen absorption in rabbits.Int. J. Pharm. 5:25–32 (1980).
J. D. Conklin, R. J. Sobers, and D. L. Wagner. Urinary drug excretion in dogs during therapeutic doses of different nitrofurantoin dosage forms.J. Pharm. Sci. 58:1365–1368 (1969).
W. J. Jusko, J. R. Koup, and G. Alvan. Nonlinear assessment of phenytoin bioavailability.J. Pharmacokin. Biopharm. 4:327–336 (1976).
J. T. Lettieri and H-L. Fung. Dose-dependent pharmacokinetics and hypnotic effects of sodium γ-hydroxybutyrate in the rat.J. Pharmacol. Exp. Ther. 208:7–11 (1979).
R. K. Liedtke, S. Ebel, B. Missler, W. Haase, and L. Stein. Single-dose pharmacokinetics of macrocrystalline nitrofurantoin formulations.Arzneim. -Forsch./Drug Res. 30:833–836 (1980).
B. Hoener and S. E. Patterson. Nitrofurantoin disposition.Clin. Pharmacol. Ther. 29:808–816 (1981).
N. Inotsume and M. Nakano. Reversible azomethine bond cleavage of nitrofurantoin in acidic solutions at body temperature.Int. J. Pharm. 8:111–119 (1981).
J. A. Buzard, J. D. Conklin, È. O'Keefe, and M. F. Paul. Studies on the absorption, distribution and elimination of nitrofurantoin in the rat.J. Pharmacol. Exp. Ther. 131:38–43(1961)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Watari, N., Funaki, T., Aizawa, K. et al. Nonlinear assessment of nitrofurantoin bioavailability in rabbits. Journal of Pharmacokinetics and Biopharmaceutics 11, 529–545 (1983). https://doi.org/10.1007/BF01062210
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01062210